Discovery of potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitors possessing a key intramolecular hydrogen bond – Part 2. Issue 4 (15th February 2019)
- Record Type:
- Journal Article
- Title:
- Discovery of potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitors possessing a key intramolecular hydrogen bond – Part 2. Issue 4 (15th February 2019)
- Main Title:
- Discovery of potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitors possessing a key intramolecular hydrogen bond – Part 2
- Authors:
- Shore, Daniel G.M.
Sweeney, Zachary K.
Beresford, Alan
Chan, Bryan K.
Chen, Huifen
Drummond, Jason
Gill, Andrew
Kleinheinz, Tracy
Liu, Xingrong
Medhurst, Andrew D.
McIver, Edward G.
Moffat, John G.
Zhu, Haitao
Estrada, Anthony A. - Abstract:
- Graphical abstract: Highlights: A series of potent azaindazole inhibitors of LRRK2 was discovered. A putative intramolecular hydrogen bond was crucial for LRRK2 potency. Optimization led to potent, metabolically stable, and brain-permeable molecules. Compound18 showed excellent LRRK2 potency and properties. Abstract: The discovery of disease-modifying therapies for Parkinson's Disease (PD) represents a critical need in neurodegenerative medicine. Genetic mutations in LRRK2 are risk factors for the development of PD, and some of these mutations have been linked to increased LRRK2 kinase activity and neuronal toxicity in cellular and animal models. As such, research towards brain-permeable kinase inhibitors of LRRK2 has received much attention. In the course of a program to identify structurally diverse inhibitors of LRRK2 kinase activity, a 5-azaindazole series was optimized for potency, metabolic stability and brain penetration. A key design element involved the incorporation of an intramolecular hydrogen bond to increase permeability and potency against LRRK2. This communication will outline the structure-activity relationships of this matched pair series including the challenge of obtaining a desirable balance between metabolic stability and brain penetration.
- Is Part Of:
- Bioorganic & medicinal chemistry letters. Volume 29:Issue 4(2019)
- Journal:
- Bioorganic & medicinal chemistry letters
- Issue:
- Volume 29:Issue 4(2019)
- Issue Display:
- Volume 29, Issue 4 (2019)
- Year:
- 2019
- Volume:
- 29
- Issue:
- 4
- Issue Sort Value:
- 2019-0029-0004-0000
- Page Start:
- 674
- Page End:
- 680
- Publication Date:
- 2019-02-15
- Subjects:
- LRRK2 -- Kinase inhibitor -- Azaindazole -- Parkinson's disease -- Brain penetration
Bioorganic chemistry -- Periodicals
Pharmaceutical chemistry -- Periodicals
572 - Journal URLs:
- http://www.elsevier.com/wps/find/journaldescription.cws_home/972/description#description ↗
http://www.sciencedirect.com/science/journal/0960894X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.bmcl.2018.10.017 ↗
- Languages:
- English
- ISSNs:
- 0960-894X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2089.330000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 9467.xml